# Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/anlotinib-as-a-third-line-therapy-in-patients-with-refractory-advanced-non-small/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Baohui Han,Kai Li,Yizhuo Zhao,Baolan Li,Ying Cheng,Jianying Zhou,You Lü,Yuankai Shi,Zhehai Wang,Liyan Jiang,Yi Luo,Yiping Zhang,Cheng Huang,Qiang Li,Guoming Wu |
| Citations | 266 |
| DOI | 10.1038/bjc.2017.478 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://www.nature.com/articles/bjc2017478.pdf |
| OpenAlex ID | https://openalex.org/W2791602004 |
| PMID | 29438373 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Baohui Han](https://scholariq.org/researchers/baohui-han/)
- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [You Lü](https://scholariq.org/researchers/you-lu/)

## Paper journal

- [British Journal of Cancer](https://scholariq.org/journals/british-journal-of-cancer/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.